Three's company: Sanofi follows lead of Lilly and Novo, slashes insulin price by 78% and caps out-of-pocket costs
Sanofi today joined with the other two insulin juggernauts in the US to lower the price of its best-selling insulin product, Lantus (insulin glargine), by 78% and set a $35 cap on out-of-pocket costs for Lantus for all patients with commercial insurance. The price shifts will begin in January 2024.
The shift from Sanofi follows Novo Nordisk’s up to 75% price cuts for its insulins, beginning in 2024, and Eli Lilly’s similar 70% discount on its popular Humalog insulin product, which will occur in the fourth quarter of this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.